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ABSTRACT 
 
 
The etiology of 80% of patients with primary antibody deficiency (PAD), the second most 
common type of human immune system disorders after human immunodeficiency virus 
infection, is yet unknown. A correct molecular diagnosis in patients with primary 
immunodeficiencies is crucial for the classification of these disorders with a heterogeneous 
clinical/immunological phenotype and subsequent therapeutic management. Primary 
antibody deficiency is a group of immune diseases with highly diverse clinical and 
immunologic features. Next generation sequencing and hightrouput multiomics studies has 
facilitated genetic investigations of rare inherited diseases during the past decade, thus 
allowing an appropriate diagnosis and treatment in these patients. 
Clinical and immunological phenotyping of a cohort of consecutive 
dysgammaglobulinemic patients with unknown genetic defects underwent genomic (e.g. 
whole-exome sequencing) and other relative multiomics (e.g. transcriptomics, proteomics, 
epigenomics and immunomics) investigations after having been subjected to classical 
targeted sequencing. 
Exome sequencing analysis was performed on 126 PAD probands (55.5% male, 95.2% 
childhood onset) born to predominantly consanguineous parents (82.5%) and thus expected 
to carry homozygous mutations with an autosomal recessive pattern of inheritance. This 
genomic approach and subsequent immunological investigations identified potential 
disease-causing variants in 86 patients (68.2%), however, 27 of these patients (31.4%) 
carried autosomal dominant (7%) and X-linked (24.4%) gene defects. Using this advanced 
method and multiomics confirmatory studies, we described new phenotypes of known 
genes (Paper I, III), new inheritance pattern of known genes (Paper II) and discovered a 
new gene in human disorder (Paper IV). Clinical and immunologic phenotypes of the 
remaining unsolved 40 patients were compared with patients with identified molecular 
defects. Medical implications of the definite molecular diagnosis were reported in ~50% of 
the patients, including hematopoietic stem cell transplantation, follow-up visits schedule 
and tertiary preventive screening tests (such as reducing radiation exposure for 
radiosensitive patients), targeted medication and prenatal diagnosis. Finally, we propose a 
clinical/immunologic workup followed by a standard genomic and multiomics analysis for an 
approach to PAD patients (Paper V). 
Due to misclassification of the conventional clinical and immunological phenotyping for 
targeted sequencing, employing next generation sequencing as a preliminary step of 
molecular diagnosis approach to patients with dysgammaglobulinemia is essential and 
could help in many facets of management and treatment of the patients and their family 
members. This study also illustrates the power of exome sequencing in the identification of 
novel and candidate genes underlying primary antibody deficiency and nesciciate 
confirmatory multiomics functional assays. The findings of this study demonstrate a new 
workup and clinical guideline to approach patients with different types of 
dysgammaglobulinemia and highlight the importance of multiomics approach in the filed of 
clinical immunology.  
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POPULAR SCIENCE SUMMARY 
 
 
Just or False; How may the B cells orchestra be tuned? 
 
As a part of our well programmed and designed immune system, B cells work with high-
quality sound instruments to bring our body into a state of internal and external harmony. 
Think of B cell as an orchestra, which has many different instruments with different expert 
performers making up its whole with different sounds that suit different audiences. They 
follow the music notes generated in the brain of the conductor (DNA) and delivered as a note 
page (RNA) to make beautiful melodies of peace (proteins of antibodies) against external 
sorrows (pathogens and allergens) and internal griefs (aging and intolerance).  
 
If a part of this concert is not “in tune” and vibrating at the correct frequency, or if the 
musician is emotionally under par or mentally overburdened, the result is a stressed, under 
functioning music that feels as if being everything from unwell down to quite ill (infections, 
allergies, autoimmunity and cancers). This “dis-ease” of B cells should be detected and can 
be aided by the application of sound to re-tune, and start to bring about internal and external 
harmony if we understand which stage has the issue.  
 
Best songs needed for the beginning of a harmonic life is delivered by our mothers love (IgG 
from umbilical cords and IgA from breast milk). However, after 6 months of age all children 
should orchestrate their own bands of B cells to practice and generate their own life songs. 
Unfortunately, the conductor (DNA) is not always in a good mood in all humans to act 
onetime or functional. Without proper conductor for the orchestra there will sometimes be no 
products (agammaglobulinemia) or low dysfunctional products (hypogammaglobulinemia). 
Without the optimal achievement of the top-level goal of harmony, which is the responsibility 
of the conductor, the body will be faced with infections, allergies, autoimmunity and cancers 
from early years of life.  
 
Although the B cells orchestra contains many other components, including the players and 
their instruments (IgA, IgG, IgM, IgE and IgD producers), and although each of these 
components can affect the goal-oriented function if they misbehave, it is logical to start to 
investigate the conductor first in the case of chaos (genomic investigation). The reason being 
that only the conductor is in a position to oversee the achievement of the top-level goal. 
According to the high reflective B cells orchestra, the impact of the failed conductor can be 
found systematically in the other functions of the group (in a different level of epigenome, 
transcriptome, proteome, and immunome).  
 
Just because we do not yet know the meaning of every note of B cells orchestra’s conductor 
in the human, it does not mean we cannot find the reason for 80% of dysfunction of this 
orchestra. Much progress in immune system knowledge consists of more and more detailed 
understanding of how each note is represented in particular B cells and in particular 
subclasses of B cells. There is no reason to suppose that this progress will not continue, until 
such point where we can account for the representation of those meanings which correspond 
to our "folk antibodies music" intuitions about the central control mechanisms of the 
orchestra. This study took some of the wrong notes into account, quog (DNA mutations), 
which affects the emotional experience of listening to a sensational music in some of my 
patients, that impeded them from undergoing a whole range of emotions that they deserved to 
experience from their B cells orchestra.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Rimligt eller Falskt; Hur kan B-cellens orkester stämmas? 
Som en del av vårt välprogrammerade och utformade immunsystem arbetar B-celler med 
högkvalitativa ljudinstrument för att få vår kropp i ett tillstånd av intern och extern harmoni. 
Tänk på B-cellen som en orkester, som har många olika instrument med olika expertartister 
som gör det hela med olika ljud som passar olika publik. De följer de musikanteckningar som 
genereras i ledaren (DNA) och levereras som en anteckningssida (RNA) för att skapa vackra 
melodier av fred (proteiner av antikroppar) mot externa sorger (patogener och allergener) och 
inre sorger (åldrande och intolerans). 
 
Om en del av den här konserten inte "stämmer" och vibrerar med rätt frekvens, alternativt om 
dirigenten är emotionellt nedstämd eller psykiskt överbelastad, är resultatet en stressig, 
undermålig musik som förmedlar otrevliga förnimmelser i alltifrån obehag till 
sjukdomskänsla (infektioner, allergier, autoimmunitet och cancer). Detta tillstånd med B-
cellerna bör detekteras och kan, om vi förstår vilket stadium i processerna som har problemet, 
mildras genom att använda ljudet för återjustering och införande av intern och extern 
harmoni.  
 
Bästa sångerna som behövs i början av ett harmoniskt liv levereras av våra mödrars kärlek 
(IgG från navelsträngar och IgA från bröstmjölk), men efter 6 månaders ålder borde alla barn 
organisera sina egna band av B-celler för att träna och generera sina egna livssånger. Tyvärr 
är ledaren (DNA) inte alltid i gott humör hos alla människor för att förmå agera 
funktionsenligt. Utan korrekt ledare för orkestern kan produkterna utebli 
(agammaglobulinemi) eller så blir resultatet dysfunktionella produkter 
(hypogammaglobulinemi). Med avsaknad av uppnått,  överordnat mål av harmoni - vilket är 
ledarens ansvar - kommer kroppen att möta infektioner, allergier, autoimmunitet och cancer 
redan i början av livet. 
 
 
Även om B-cellerna innehåller många andra komponenter - inklusive spelarna och deras 
instrument (IgA-, IgG-, IgM-, IgE- och IgD-tillverkare) och även om underfunktion i en enda 
komponent av dessa kan inverka på den målorienterade funktionen - är det logiskt att börja 
undersöka ledaren först gällande dessa tillstånd (genomisk utredning). Detta eftersom endast 
ledaren är i position att övervaka det överordnade målet att allt fungerar som det skall. Enligt 
den högreflekterande B-cellorkestern kan effekten av en dysfunktionell - ”misslyckad” - 
ledare hittas systematiskt i gruppens övriga funktioner (i olika nivåer av epigenom, 
transkriptom, proteom och immunom). 
 
 
Bara för att vi ännu inte känner till betydelsen av varje anteckning från B-cellorkesterens 
dirigent i människan, innebär inte detta att vi inte kan hitta orsaken till 80% av alla kända 
dysfunktioner i  denna orkester. Mycket av framstegen i kunskapen om immunsystemet 
utgörs av ökad detaljerad förståelse av hur varje ”nota” representeras i specifika B-celler  
samt inom specifika underklasser av B-celler. Det finns ingen anledning att anta att denna 
utveckling inte kommer att fortsätta, tills en sådan punkt där vi kan förklara representationen 
av den innebörd som motsvarar vår ”antikroppsmusik”-metafor om orkesterns centrala 
kontrollmekanismer. Denna studie fastslog några av de felaktiga ”musikanteckningarna” - 
DNA-mutationerna - vilka påverkar den hos mina patienter känslomässiga erfarenheten av att 
lyssna på sensationell musik. Det hindrar dem från att uppleva en rad känslor som de 
förtjänar att erfara från deras B-cellorkester.  
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1 INTRODUCTION 
1.1 PRIMARY ANTIBODY DEFICIENCIES 
Primary antibody deficiency (PAD) is the most common form of primary 
immunodeficiency (PID), with a prevalence of about 1 in 600 in the general population [1, 
2]. The clinical picture is highly variable (ranging from asymptomatic to severe) and 
includes infection, autoimmunity, lymphoproliferation, enteropathy and malignancy [3-5]. 
The wide spectrum of immunological presentations of PAD constitutes B-cell lymphopenia, 
agammaglobulinemia, hyper-IgM syndrome, hypogammaglobulinemia, isotype deficiencies 
as well as a transient form of a humoral immunodeficiency (Figure 1). Several mutations in 
PAD patients that play key roles in B-cell activation, proliferation, differentiation, class-
switch recombination, somatic hypermutation and apoptosis have been identified; however, 
the etiology remains unknown in a majority of the patients [4, 6-10].  
 
 
Figure 1- Model of pathogenesis in dysgammaglobulinemia representing different 
immunologic phenotypes based on the maturational arrest in different steps of B-cell 
development. HSC: hematopoietic stem cell CLP: common lymphoid progenitor, IB: 
immature B cells, TB: transitional B cells, NB: naïve B cells, MZB: marginal zone B cells, 
AMZB: activated marginal zone B cells, Breg: regulatory B cells, FB: Follicular B cells, AB: 
activated B cells, Ab-dep: antibody dependent, GCB: germinal center B cells, MB: memory 
B cells, PbB: Plasmabalst B cells, PcB: Plasmacells Bcells, AGG: agammaglobulinemia, 
CVID: common variable immunodeficiency, HIgM: hyper-IgM syndrome, HGG: 
hypogammaglobulinemia, IgAD: IgA deficiency, SAD: specific antibody deficiency, ISD: 
IgG subclass deficiency, THI: transient form of a humoral immunodeficiency. 
 
According to non-redundant functions of different types of antibodies, several immune 
functions (Fab-mediated and Fc-mediated) may be disturbed as a consequence of PAD. 
Fab-mediated functions includes antigen recognition (against all types of molecules 
including carbohydrates, nucleic acids and phospholipids but are best suited to bind a 
polypeptide pathogens and allergens), neutralization of surface proteins and toxins 
(prevents the access of the pathogen to the host receptors and prevents destruction of host 
cells by dimeric mucosal IgA) and providing first line of systemic defense (binding to 
multivalent antigens by pentameric IgM antibodies rapidly generated in blood) and targeted 
defense (by diffusing IgG into the tissues). Fc-mediated effector functions of antibodies 
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provide activation of effector cells (including phagocytic cells like macrophages and 
neutrophils, T cells like natural killer cells, eosinophils and mast cells using receptor for the 
Fc fragment), complement binding (activates complement cascade and release of chemical 
mediators from mast cells, reinforce phagocytosis and cell lysis) and opsonization (coated 
antibodies at surface of the pathogen allow binding of Fc domains to Fc receptors present 
on scavenger cells) [11-14]. 
 
1.2 GENETIC DEFECTS CAUSING PRIMARY ANTIBODY DEFICIENCIES 
B cells development and its cellular interactions have a central role in the humoral immune 
response and antibody production /secretion. B cell development begins in bone marrow and 
continues in secondary lymphoid organs. Expression of different lineage-specific markers on 
B cell precursors indicates different stages of B cell development.  
Several gene products are responsible for early B cell development in bone marrow. The 
classical gene from this group is known as Bruton tyrosine kinase (BTK). Figure 2 represents 
other involved genes in early B cell development and B cell receptor signaling. Mutations in 
genes involved in this step of development result in severe PAD, which is characterized by 
blockade of B cell differentiation before the production of surface Ig, markedly reduced 
mature B cell counts in the peripheral circulation, profound hypogammaglobulinemia or 
agammaglobulinemia, and early onset of recurrent bacterial infections in affected children 
[15]. 
 
Figure 2- Discovered cytoplasmic and membrane molecules encoded by genes involved in 
B-cell development and known to be involved in primary antibody deficiencies due to their 
role mainly in early development (in bone marrow depicted by blue), class switching 
recombination (in the secondary lymphoid organs depicted by green) and terminal 
maturations of B cells (depicted by red) [16-19, 7, 10].  
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In secondary lymphoid organs, class-switch recombination (CSR) and somatic hypermutation 
(SHM) are the mechanisms necessary for the generation of effector plasma cells secreting 
high-affinity IgG, IgA, and IgE antibodies. The classical gene that plays a key role in CSR 
and SHM is CD40 ligand (CD40L) and Figure 2 depicts the remaining involved known 
genes in this process. Defects in CSR are characterized by low serum levels of IgG, IgA, and 
IgE leading to recurrent bacterial infections associated with normal or elevated serum IgM 
levels [20, 21].  
The terminal stages of B-cell development are also controlled by different genetic signatures 
including TNF receptor superfamily members, CD19–B cell receptor (BCR) complex, the B-
cell differentiation cytokines and apoptosis/autophagy pathways (Figure 2) [22]. 
Approximately 30 genes causing B cell developmental defects in humans have been 
described since 1952 to 2013 prior to starting of this Ph.D. study. Furthermore, the largest 
gap between clinical and molecular diagnosis in the field of PID is seen in patients with PAD 
(Table 1) [23]. Close to 90% of patients with late B cell development disorders, 10% of cases 
with a defect in early B cell development and 10% of those with a CSR defect have no 
definite causative gene mutation. 
 
 
Table 1. Frequency of patients of each category of primary immunodeficiencies in Iran. 
Category  Probable 
prevalence 
Expected 
frequency 
Clinically
diagnosed (n; %) 
Definitely 
diagnosed (n; %) 
Combined immunodeficiencies  1/50,000 1528 265 (17.3) 21 (7.9) 
Syndromic  immunodeficiency  1/100,000 764 271 (35.5) 80 (29.6)
Predominantly antibody deficiencies  1/650 117,394 545 (0.5) 77 (14.4)
Diseases of immune dysregulation  <1/1,000,000 76 80 (105.3) 52 (65) 
Congenital defects of phagocytes  1/250,000 306 390 (127.4) 95 (24.4)
Defects in innate immunity  <1/1,000,000 76 36 (47.4) 6 (16.6) 
Autoinflammatory disorders  1/10,000 7642 580 (7.59) 490 (84.5)
Complement deficiencies 1/50,000 1528 32 (2.1) 0 (0) 
Total  ≥1/600 ≥127,300 2199 (1.76) 790 (35.2)
 
 
1.3 CLINICAL CONCEPT OF MOLECULAR DIAGNOSIS OF PRIMARY 
ANTIBODY DEFICIENCIES 
Positive predictive values of clinical algorithms for identifying PAD range from 19.1% in 
patients with hypogammaglobulinemia to 33.3% in patients with a CSR defect presenting 
hyper-IgM syndrome in the Medicaid database [24], indicating the necessity of a correct 
genetic diagnosis. Besides confirming the clinical diagnosis, molecular diagnosis also plays 
a pivotal in the identification of new genetic defects, pre-symptomatic diagnosis, treatment 
decisions, prognosis prediction and family counseling [25]. Moreover, the clinical 
presentation of mutations in known PID genes varies due to the type of mutation (missense, 
nonsense, insertion/deletion), the protein domain involved and the presence of modifying 
genes or environmental factors. Recent reports on atypical manifestations of known 
primary immunodefciencies have revealed a role for molecular diagnosis in defining a new 
phenotype for a known monogenic disorder [26].  
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Advances in next generation sequencing (NGS) methods allow an unbiased approach to 
PAD patients in order to obtain a correct diagnosis and subsequently adjust the clinical 
management and treatment. Targeted NGS panels with several hundreds of known PID 
genes may provide a first screening step, thus improving the classical approach of the 
sequencing of selected candidate genes [27]. Nevertheless, this method is not sufficiently 
efficient due to the heterogeneous nature of these diseases, resulting in a clinical sensitivity 
of 15-40% in PID patients [28-31]. For the time being, whole exome sequencing (WES) 
seems to be the most cost effective approach for genomic evaluation of PAD patients with an 
unknown etiology due to our current cognition about monogenic disorders (enriched in 
coding exome the most conserved region of the genome across metazoans), and less analysis 
complexity and risk of incidental findings [32]. Moreover, the majority of previous studies 
have only focused on patients with hypogammaglobulinemia, and the molecular basis of a 
considerable proportion of patients with other forms of PAD remains unknown, particularly 
in high-frequency disorders such as selective IgA deficiency and IgG subclass deficiency 
[18, 33]. 
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2 AIMS 
2.1 GENERAL RESEARCH AIM 
The aim of this study was to perform WES of a substantial number of PAD patients with 
unidentified genetic defects and to investigate its impact on the clinical diagnosis and 
subsequent clinical management.  
 
2.2 SPECIFIC SCIENTIFIC AIMS 
2.2.1 To functionally characterize the genes involved in patients with early B cells defects 
without identified genetic causes and to provide a clinically and immunologically relevant 
summary.  
2.2.2 To functionally characterize the genes involved in patients with CSR defects without 
identified genetic causes and to provide a clinically and immunologically relevant summary.  
2.2.3 To functionally characterize the genes involved in patients with terminal B cell defects 
without identified genetic causes and to provide a clinically and immunologically relevant 
summary.  
2.2.4 To design, develop and benchmark a complete cost-effective multiomics approach to 
PAD patients starting with genomic step and followed by relevant confirmatory functional 
assays.  
2.2.5 To evaluate the feasibility and usefulness of current genomic approach in the field of 
clinical immunology, and to solve pitfalls in the analysis steps and pipelines designed for 
molecular diagnosis using next generation sequencing.  
2.2.6 To improve the performance of in-silico analysis after identification of candidate 
genetic defect by integration of computational models and predicative software.  
 
2.3 TRANSLATIONAL AIM 
The translational aim of this thesis was to provide clinicians treating patients suffering from 
PADs with updated clinical, laboratory and mutation analyses for selected cases with early 
onset of the disease and a high consanguinity rate. Moreover, we have tried to suggest new 
modalities for targeted treatment of the patients according to the discovered gene and consult 
patient and patients’ family with appropriate carrier detection and genetic counseling. Finally, 
we propose a clinical/immunologic workup followed by a standard genetic analysis for an 
approach to PAD patients. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
Among all registered symptomatic PAD patients in the Iranian national PID registry [34], 
available individuals who were referred to Children’s Medical Center (Pediatrics Center of 
Excellence affiliated to Tehran University of Medical Sciences, Tehran, Iran) were 
consecutively recruited into this study. Informed consent (including explanations about the 
risks and benefits of research-based NGS) for the performed studies was obtained from all 
patients and their relatives, according to the principles of the ethics committee of the Tehran 
University of Medical Sciences and the Karolinska Institutet. An evaluation document was 
used to summarize the demographic information of the patients, including gender, date of 
birth, clinical parameters and previous medical history, family history, and laboratory and 
molecular data. Consanguinity of parents was evaluated by interview. All patients were 
diagnosed as PAD based on the updated diagnostic criteria of ESID (the European Society for 
Immunodeficiencies, http://esid.org/WorkingParties/Registry/Diagnosis-criteria) and 
AAAAI (The American Academy of Allergy, Asthma & Immunology) practice parameter for 
the diagnosis and management of PID [35], including agammaglobulinemia, hyper-IgM 
syndrome (HIgM), common variable immunodeficiency (CVID), IgA deficiency (IgAD), 
IgG subclass deficiency, specific antibody deficiency and transient hypogammaglobulinemia. 
All patients were re-evaluated for fulfilling either the probable or possible diagnostic criteria. 
Secondary causes of dysgammaglobulinemia were ruled out. A computerized database 
program (new registry section at http://rcid.tums.ac.ir/) was designed for final data collection 
and direct summarizing/analysis of data. 
3.2 MULTIOMICS STRATEGY 
3.2.1 Genomic Approach 
WES was performed on PAD patients without any known underlying genetic defects. To 
classify a patient as undefined PAD, a classic genetic analysis was performed for patients 
with agammaglobulinemia (mutations in the BTK, BLNK, CD79A, CD79B, IGLL1 and IGMH 
genes) and HIgM syndrome (mutations in the CD40L, CD40, AICDA and UNG genes) using 
targeted sequencing  [36-38], whereas other forms of dysgammaglobulinemia (including 
CVID and IgAD) were considered as undefined forms of PAD at baseline and directly 
recruited for WES.  
For patients with undefined PAD, 6µg extracted genomic DNA was randomly fragmented, 
amplified by ligation-mediated polymerase chain reaction (PCR) and captured and sequenced 
according to the protocol described previously [39]. After raw image file processing, 
sequences were generated and aligned to the human genome reference (UCSC hg 19 version; 
build 37.1) using the SOAP aligner software (Short Oligonucleotide Analysis Package, 
v.2.21). Duplicated reads were filtered out and only uniquely mapped reads were kept for 
subsequent analyses. The SOAPsnp software (v.1.03) was subsequently used with default 
parameters to assemble the consensus sequence and call genotypes in target regions. Low-
quality single nucleotide polymorphisms (SNP) that met one of the four following criteria 
were filtered out: a genotype quality of less than 20 bp; a sequencing depth of less than 4; an 
estimated copy number of more than 2 and a distance from the adjacent SNPs of less than 5 
bp. Small insertions/deletions (Indels) were detected using the Unified Genotype tool from 
GATK (Genome Analysis Toolkit ,v.1.0.4705) following the alignment of quality reads to the 
human reference genome using BWA (Burrows-Wheeler Aligner, v.0.5.9-r16). For analysis 
of WES, we followed the protocol described previously for prioritizing candidate variants, 
  7 
predicting their effect on protein, homozygosity mapping, large deletion and copy number 
variation (CNV) detection [39].  
The pathogenicity of all disease attributable gene variants was re-evaluated using the updated 
guideline for interpretation of molecular sequencing by the American College of Medical 
Genetics and Genomics (ACMG), considering allele frequency in the population database, 
computational data, immunological/functional data, familial segregation, parental data and 
clinical phenotyping  [40].  
To validate the mutations observed and complete familial segregation, Sanger sequencing 
was performed. Specific primers for each mutation were designed using PRIMER3 Input 
version (0.4.0) software (bioinfo.ut.ee). Standard PCR was performed in a final volume of 15 
µl containing 10 ng of genomic DNA. Amplified products were resolved in 1% agarose gel 
and purified using the NucleoSpin kit (Macherey-Nagel GmbH). The resulting PCR products 
were sequenced at the Macrogen Company, South Korea. The sequences were analyzed using 
the Lasergene software package (DNAStar, Madison). 
The observed mutations were classified as a novel (newly identified in PAD patients), new 
phenotype (PID gene known to be disease causing with a new presentation) or known 
phenotype (PAD gene with a typical presentation) [41, 42]. Genotype and phenotype 
correlations were integrated and clinical implications of the molecular diagnoses were 
evaluated.  
 
3.2.2 Transcriptomic Approach 
Total RNA was isolated from peripheral blood mononuclear cells (PBMC, extracted by 
standard Hypaque-Ficoll, GE Healthcare) using the RNeasy Mini kit (Qiagen). 
Complementary DNA (cDNA) was synthesized using the RevertAid first strand cDNA 
synthesis kit (Fermentas). Mutant genes mRNA levels were quantified by quantitative real-
time PCR using the 2e-ΔΔCt relative method and a known gene was used as a housekeeping 
gene for normalization. The PCRs were run in a StepOne Instrument (StepOne Software 
v.2.3, Applied Biosystems, Life Technologies Corporation). 
 
3.2.3 Proteomic Approach 
PBMCs were isolated from whole blood based on the abovementioned density gradient 
centrifugation, cryopreserved in freezing medium (Synth-a-freeze CTS, Life Technologies) 
for further proteome. Before the proteomic investigation, PBMCs were thawed and washed 
twice in R10 (RPMI-1640 Medium AQmedia, Sigma Aldrich) containing 10 % fetal bovine 
serum, 50 IU/mL penicillin and 50 g/mL streptomycin. 
For direct Western Blotting, PBMC extracts were boiled for 5 minutes in Radio Immuno-
Precipitation Assay lysis buffer (RIPA buffer). Protein concentrations were measured by the 
Pierce bicinchoninic acid (BCA) protein assay (ThermoFisher Scientific). Equal amounts of 
protein were separated on a 10% Sodium dodecyl sulfate (SDS)-polyacrylamide gel and 
blotted onto a nitrocellulose membrane (Hybond-ECL, GE healthcare, Little Chalfont, 
Buckinghamshire). The membrane was blocked with PBS-T (Phosphate buffered saline, 
0.05% Tween 20, 5% milk powder). Membranes were subsequently incubated with 
polyclonal antibodies against either the studied gene’s product or a housekeeping protein. 
They were then incubated with horseradish peroxidase-conjugated (HRP) labeled secondary 
antibodies in appropriate dilution. The signal was detected by chemiluminescence using the 
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enhanced chemiluminiscence (ECL) Plus™ Western Blotting detection system (GE 
Healthcare) with the GeneSys software (v.1.4.1.0, Syngene) and evaluated by densitometry 
(GeneTools software v.4.03, Syngene). 
The protocol for extracellular and intracellular staining of flowcytometry evaluation of 
lymphocytes and the related functional markers has previously been described elsewhere 
[43]. Briefly, cells were counted on a Nucleocounter (ChemoMetec A/S), resuspended in R10 
containing 10 U/mL DNase I (Roche Diagnostics) and rested for 7 hours at 37 C. U-bottom 
plates were plated with 5-10 × 105 PBMCs/well. Regarding functional analysis, cells were 
also supplemented together with designed stimuli at the start of the stimulation protocol at 
37C 5% CO2 incubation [44]. Cells were stimulated for 10 hours. The cells were transferred 
to V-bottom plates, washed in fluorescence-activated cell sorting (FACS) buffer and stained 
with a LIVE/DEAD Aqua amine dye solution containing the extracellular antibodies for 30 
minutes. PBMCs were washed in FACS buffer and fixed/permeabilized using the forkhead 
box P3 transcription factor buffer kit (eBioscience, San Diego, CA). In case of required 
evaluation, monoclonal antibodies against intracellular markers were incubated with the cells 
for 1 hour. After further washing with Perm Wash solution (eBioscience), the cells were 
resuspended in PBS containing 1 % paraformaldehyde. PBMCs were analyzed on a 4 laser 
LSR Fortessa (BD Biosciences), where minimally 150,000 events were collected per run. 
Antibody capture beads (BD Biosciences) were stained individually with all antibodies used 
in the experiments for compensation setup. Gating analysis was performed using FlowJo 
8.8.7 (Treestar). Manual gates were based on unstained cells or fluorescence minus one 
(FMO) gating strategies as previously described [45, 46].  
Regarding evaluation of proteome in the serum samples, the Sandwich enzyme-linked 
immunosorbent assay (ELISA) measures the amount of protein of interest between two layers 
of antibodies (i.e. capture and detection antibody). Briefly, 96-wells ELISA microtiter plate 
was coated with the capture antibody in PBS and was incubated overnight at 4°C.  The 
remaining protein-binding sites of plates were blocked using a blocking buffer, and then 
diluted samples and standards (triplicates) were applied for accurate quantitative results and 
to compare the signal of unknown samples against those of a standard curve. After washing 
steps, secondary antibody biotin-conjugated, diluted at the optimal concentration in blocking 
buffer, were added. The substrate for HRP was coupled to oxidation of a hydrogen donor 
which changes color during the reaction and TMB (3,3’,5,5’-tetramethylbenzidine) solution 
was used for detection. After implication of stopping solution (1M H2SO4) plate were read 
the optical density at 450 nm using ELISA reader (Varioskan™ LUX, Thermo Fisher).  
In selected patients, specific methods for functional tests of the candidate gene were 
implemented including transduced cell line using vectors carrying mutant versus wild type 
gene, cytotoxic T and NK cell killing assays, and virus-specific cytotoxic T cell activation 
[47-49]. 
 
3.2.4 Immunomic Approach 
Complete blood count, lymphocyte subpopulations, serum immunoglobulin (Ig) levels and 
specific antibody response were measured as previously described [47, 50-56]. We classified 
our patients based on two main classifications for B-cell subsets including the EUROclass 
classification [57] and the B-cell pattern classification [58].  
Genomic DNA and cDNA synthetized from RNA extracted from PBMCs were subsequently 
used for a nested PCR assay to amplify the recombined fragments from in vivo switched B-
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cells (to evaluated switch recombination junctions) and somatic hypermutation rate as 
previously described [59].  
In patients with a progressive decreased levels of lymphocytes, T-cell recombination excision 
circles (TREC) and kappa-deleting element recombination circle (κREC) analysis were 
performed on genomic DNA samples according to the previously published protocol [60]. 
 
3.3 STATISTICAL ANALYSES AND BIOINFORMATICS 
Statistical analysis was performed using a commercially available software package (SPSS 
Statistics v.17.0.0, SPSS, and R statistical systems v.3.4.1., R Foundation for Statistical 
Computing). One-sample Kolmogorov-Smirnov test was applied to estimate whether data 
distribution is normal. Parametric and nonparametric analyses were performed based on the 
finding of this evaluation. A p-value of 0.05 or less was considered statistically significant. 
Several software was used for In-silco analysis regarding positive selection detection, 
population structure detection, population structure inference, haplotype phase inference, 
familial aggregation analysis, cluster analysis, pedigree drawing and reconstruction, motif 
search, secondary structure prediction and connectome/pathway analysis [47-49, 61]. 
 
3.4  REFLECTIONS ON ETHICAL CONSIDERATIONS IN THE PROJECT 
The basis for this project was an exploration of the genome of patients affected by a group of 
inherited disorders of the immune system, entitled PAD. Most of the patients in this category 
of disorders are children with chronic complications. Based on the purpose of this project, we 
needed to collect and record all medical data, family history, complete clinical examination 
and immunological investigation of each individual as well as the results of WES and the 
multiomics functional assays. In the last stage of the project, we also performed carrier 
detection in the siblings and first-degree relatives of the index case. 
In this study, according to the methods of research, we followed the ethical guideline 
concerning following issues dealing with human subjects, children, mental incomplete 
persons, principles for using human tissues and samples and genetic study. For all patients in 
the PAD registry, participation in genetic screening and definite molecular diagnosis were 
voluntary (autonomy) and in the informed consent form, we have declared that the results 
will not be disclosed to employers, insurers, or others without the individual's consent (if the 
patient needs the certificate for completion of the insurance), in order to avoid possible 
discrimination.  
We have declared to the PAD patients that we are responsible for research information to 
provide the patients with the outcome of the project unless s/he refrains from receiving the 
information. We have also guaranteed that all information will be considered as confidential. 
For both adult and pediatric patients informed consent has been given under the complete 
freedom and with a reasonable amount of time for decision without any force, threat, allure or 
temptation. All registered individuals have been treated based on the updated standard 
treatment, even if they declined enrollment in the study. We respected the patients’ privacy 
and kept their private information confidential as well as respecting their right to change their 
mind, to decide to withdraw early or late the project without any consequences. By the 
outcome of the study and information that might emerge in the course of research, we have 
committed to updating patients and their legal guardian about the outcome even if it might 
change their assessment of the risks and benefits of participating as well as what were learned 
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from the research. Within the informed consent, we depicted for all registered PAD patients 
the aims, methods, anticipated benefits (as mentioned above), the duration of the 
investigation and potential risk (PAD patients require monthly Ig troughlevel test, therefore 
we merged our sampling with this patients’routine lab test to not increase the risk of 
needling). 
Since the majority of the current PAD registry consists the children due to the nature of these 
inherited disorders, special consideration was taken to account for following ethical 
guidelines for research on pediatric cases. The study has conducted only on the child if we 
could not conduct it on adults (in families with multiple cases and with aggregation of 
patients with different ages the adult cases have been prioritized). Although the genetic 
investigations in the PAD children have both benefits and detrimental effects, it has been 
proven that beneficial effects for the next generations are not ignorable. However, in a patient 
with severe medical conditions, risk evaluation to patient’s participation in our research 
project has been done by a committee including parents or legal guardian, investigators, 
professionals, the ethics committee, and even children. 
In the current study to obtain consent from children, we have divided them into two groups: 
under 7 years and 7-15 years old.  In patients <7 years, the consent is obtained from a legal 
guardian and every effort is made to satisfy the child, while if the child was in the age range 
of 7-15  year both patient and the legal guardian have been asked to fill in the consent form 
and in cases where the decisions differed, the ethics committee was involved. As the 
investigator of this study are aware that children should be involved in decision making for 
their health and safety, we give them the right to receive useful information as much as they 
can understand, to express their opinion and to decide. The method of giving information and 
obtaining consent in the second group of PAD has been adopted for their age and their level 
of understanding.  
Of note, some PAD patients with probable defects in genes involving in the process of DNA 
repair have syndromic features accompanied by neurological symptoms and mental 
incompetence of decision, therefore, if for any reason the adults and/or child patient cannot 
make a decision, the patient's legal guardian has been asked to contribute to the consent form. 
For assessing the patient's capacity for decision making about participation in the study, the 
patient’s family physician, who was not part of the research team could be requested to judge, 
otherwise, an unrelated physician had to mediate. In this group of patients if the medical 
evaluation revealed an improvement in the mental condition further tries have been done to 
receive the patients’ consent as well. Furthermore, there are several PAD cases with these 
syndromic diseases that they cannot decide for themselves, but they can introduce another 
person into decision making, so far we have considered this request for substituting the 
person by informing the ethical committee. By the way, the investigators excluded the patient 
from the project if s/he had severe emotional problems such as suicide attempts and 
supportive care and patient was referred to the psychiatrists.  
For all, three categories of the patients including adults, children, and mentally retarded 
patients genetic results have been followed by genetic counseling, family planning 
particularly when they indicate the direct association or causality effect on the clinical 
condition.  As it happened often during the process of our study and as we had planned based 
on the finding of the genetic test, the therapeutic modalities have been revised by the panel of 
experts and if treatment or prevention was available, this has been prescribed as soon as 
possible. For example, the treatment of several cases should change from intravenous 
replacement therapy to the hematopoietic stem cell therapy and bone marrow transplantation. 
Finally, the team of the project attempt to inform patients and their families, at regular 
intervals, of new developments in testing and treatment. 
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4 RESULTS AND DISCUSSION 
4.1 WHOLE EXOME SEQUENCING IN DYSGAMMAGLOBULINEMIA 
A correct molecular diagnosis in patients with PID is crucial for the classification of disorders 
with a heterogeneous clinical/immunological phenotype and subsequent therapeutic 
management. As the above mentioned PAD have highly diverse clinical features and, in most 
cases, an as yet unknown etiology. NGS has facilitated genetic investigations of rare inherited 
diseases during the past decade, thus allowing an appropriate molecular diagnosis in these 
patients. Clinical and immunological phenotyping were documented for a cohort of 
consecutive dysgammaglobulinemic patients with unknown genetic defects after having been 
subjected to classical targeted sequencing and they underwent WES analysis using a 
previously described filtering pipeline [39]. 
4.1.1 Demographic Features of Undefined Primary Antibody Deficiencies 
 
Among all registered PAD patients (n=545, 27.2% of all patients in our PID registry), 
molecular defects were found in 49 individuals with agammaglobulinemia and 28 patients 
with HIgM syndrome using conventional genetic methods and 342 were deceased or 
unavailable for molecular investigation.  
 
The 126 remaining available patients (70 males, 56 female) from 109 unrelated kindreds were 
classified as undefined PAD and enrolled for WES (Table 2). Although the national registry 
encompasses all age ranges of PAD patients, most patients were children and adolescents at 
the time of the study (52.3% were less than 18 years old) and parental consanguinity was 
recorded in 82.5 %. The median age of the patients at the onset of symptoms was 2 years 
(range 0.5–36 years; early onset manifestation in 95.2%) and the median diagnostic delay (the 
gap between the onset of the symptoms and diagnosis of PAD) was 4 years (range 0.25–39 
years). 
 
Based on the immunologic profile of the remaining undefined patients they were classified as 
CVID in 81, HIgM in 14, agammaglobulinemia in 11, IgAD in 11, specific antibody 
deficiency in 5, IgG subclass deficiency in 3 and 1 patient was diagnosed with IgM 
deficiency. Of note, 10 patients (7.9%) progressed to a more severe form of PAD during the 
course of the disease. 
4.1.2 Molecular Diagnosis Outcome  
WES analysis and subsequent confirmatory assays resulted in a genetic diagnosis in 86 of the 
126 probands (68.2 %), where 2 patients with variants newly implicated in disease were 
identified (CD70), as well as 37 patients with known PID genes with newly identified 
phenotypes (19 unique genes), and 47 patients with mutations leading to the expected 
phenotypes (15 unique genes). Experimental data and the results of functional assays on a 
selected group of this genetically diagnosed cohort have been published in details [47, 48, 19, 
62, 61, 49, 39, 63]. 
The majority of our patients were born in consanguineous marriages and they would thus be 
expected to demonstrate an autosomal (homozygous) recessive defect. However, the mode of 
inheritance was judged to be recessive in only 23 of the 35 genes (65.7 %) accounting for 
genetic inheritance in 58 patients (67.4 %). Three genes were found to be X-linked (8.5 %) 
and 9 genes were assigned as autosomal dominant due to loss-of-function (6 genes; 17.1 %) 
or gain-of-function (3 genes; 8.5 %). 
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All disease causing variants were pathogenic or likely pathogenic based on the ACMG 
standards and were private or rare as compared to our in-house database (<1% of more than 
300 unrelated individuals sequenced), the Greater Middle Eastern variation database (<1% of 
1,111 unrelated individuals, including 168 persons from the Persian peninsula, 214 from the 
Arabian peninsula and 140 from Turkish peninsula), the Exome Aggregation Consortium 
database (<0.01% of 60,706 unrelated individuals, http://exac.broadinstitute.org/) and the 
genome AD database (<0.01% of 123,136 WES and 15,496 whole-genome sequences from 
unrelated individuals, http://gnomad.broadinstitute.org/). Of note, a large deletion of coding 
regions was identified in 4 patients carrying genetic defects within the LRBA and DOCK8 
genes. Detail of the genetic diagnosis of the different types of PAD patients is summarized in 
Figure 3. 
4.1.3 Genotypic and Phenotypic Correlation 
We decided to evaluate the genotype–clinical phenotype correlation in our cohort of PAD 
patients especially for affected individuals within the same family, using a standard method 
of phenotype subdivision which has been shown to correlate with the quality of life and 
morbidity among patients with infections only, autoimmunity, lymphoproliferation and 
enteropathy [64]. However, no significant correlation was observed, indicating an effect of 
environmental factors and/or other modifier genes on the medical complications of the 
patients.  
Table 2. Clinical characterisƟcs of 126  primary anƟbody deficient paƟents
Characteristics  Value
Sex 
Male (%)  70 (55.5)
Female (%)  56 (44.5)
Age 
Age at the time of study, year (range) 18 (4‐44)
Age of onset, year  (range)  2 (0.5‐36)
Age of clinical diagnosis, year (range) 8 (0.5‐40)
Family structure  
Non consanguineous kindress 
One affected child (%)  18 (16.5)
Two or more affected children (%) 2 (1.8)
Consanguineous kindress 
One affected child (%)  77 (70.6)
Two or more affected children (%) 12 (11.1)
Ethnicity based on Greater Middle Eastern genetic variation
Persian Peninsula  (%)  106 (84.1)
Turkish Peninsula (%)  11 (8.7)
Arabian Peninsula (%)  9 (7.2)
Clinical phenotype
Infections only (%)  40 (31.7)
Autoimmunity (%)  45 (35.7)
Lymphoproliferation (%)  47 (37.3)
Enteropathy (%) 34 (26.9)
Malignancy (%) 7 (5.5)
Allergy (%)  15 (11.9)
Overlap phenotype  48 (38.0)
Immunodeficiency diagnosis 
Common variable immune deficiency 81 (64.3)
Unsolved agammaglobulinemia 11 (8.7)
Unsolved hyper IgM syndrome  14 (11.1)
IgA deficiency  11 (8.7)
Other types of primary antibody deficiency 9 (7.2)
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Figure 3- Frequency of different monogenic defects among patients with different types of 
primary antibody deficiency as well as unsolved patients (A) among 81 patients with a 
common variable immune deficiency like phenotype and (B) 45 patients with an 
immunologic phenotype suggesting a hyper IgM syndrome (n=14) agammaglobulinemia 
(n=11), IgA deficiency (n=11), IgG subclass deficiency (n=3), specific antibody deficiency 
(n=5) and hypo IgM syndrome (n=1). 
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Given the immunologic heterogeneity of undefined PAD patients, we used the identified 
underlying gene defect to correlate potential immunopathologic mechanisms with the point 
of arrest in B-cell development using a B-cell subset analysis. An association between the 
affected gene and the pattern of abnormalities in the size of the B cell subsets were 
identified, mirroring the respective pathologic mechanism of the damaged molecule. Based 
on the observed five distinct B-cell patterns, we could demonstrate that combined B cell 
production and germinal center defects (low numbers of transitional B cells and memory B 
cells) often represent DNA repair/recombination gene defects, being associated with an 
increased radiosensitivity and a mild form combined immunodeficiency, involving the 
RAG1, DCLRE1C, PRKDC, DNMT3B and ZBTB24 genes. Early peripheral B cell 
maturation or survival arrest (loss of naive mature, marginal zone–like, and memory B 
cells) is associated with mutations in TNFRSF13B and TNFRSF13C, which is in line with 
impaired baseline constitutive activation and subsequently impaired anti-apoptotic 
signaling. Mutations in BCR associated genes (e.g. BTK, BLNK and IGMH) show a 
phenotype of both B cell activation and proliferation defects (combined reduction of the 
marginal zone–like and memory B cells). Isolated germinal center blockage (exclusive 
decrease in the number of memory B cells associated with a normal or high level of IgM) 
suggests gene defects in costimulatory molecules for T-dependent immunity (e.g. CD27, 
CD70 and ICOS) which modify signaling for class-switch recombination and somatic 
hypermutation. Finally, the pattern of post-germinal center impairment (defects in terminal 
plasma-cell maturation, survival or homing), leading to an isolated reduction of long-term 
plasma cells, might be compatible with LRBA and XIAP deficiencies (Figure 4).   
 
4.1.4 Clinical and Immunological Features of Solved versus Unsolved 
Patients 
In the 86 PAD patients with a genetic diagnosis, defects in genes that encode proteins 
involved in the post-germinal center survival pathway (LRBA and XIAP) accounted for 
19.7% of the total disease-causing etiologies while proteins involved in DNA repair and 
recombination pathways defects (RAG1, DLCRE1C, PRKDC, DNMT3B and ZBTB24) 
accounted for 17.4% of genetic defects. Defects in BCR signaling (in 13.9% of patients) and 
in the PI3K signaling pathway (phosphatidylinositide 3-kinases signaling affected in 11.6% 
of patients) were also the other frequently observed defects in our PAD cohort.  
The lowest diagnostic yield was obtained in patients with agammaglobulinemia (2 of 11 
tested; 18.1%). We performed stratification on the patients who underwent sequencing to 
determine the parameters associated with a diagnosis. Of note, consanguinity and the severity 
of clinical presentation were similar between those who had a molecular defect identified 
(n=86) and those who did not (n=40). However the clinical diagnosis of 
agammaglobulinemia (p<0.001), a late age of presentation (onset of disease > 10y; p=0.03), 
and the absence of multiple affected family members (p=0.01) were significantly more 
frequent in the patients who had no genetic defect identified. Genetic defect was identified in 
90% of patients with a progressive form of PAD suggesting a higher rate of diagnostic yield 
in this subgroup of patients compared to other patients (p=0.01). Among the 40 patients with 
non-definitive pathogenic genetic variants, immunologic phenotypes were mainly compatible 
with a pattern of post-germinal center impairment (p=0.03). 
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Figure 4- Model of the pathophysiological background of five B-cell patterns in antibody 
deficient patients based on the level of maturational arrest level. Green circles mean normal 
maturation and peripheral cell counts and red circles depict interrupted maturational step with 
decreased proliferation. HSC: hematopoietic stem cell, CLP: common lymphoid progenitor, 
ProB: Pro B-cell, PreB: Pre B-cell, IB: immature B-cell, TB: transitional B-cell, NB: naïve B-
cell, MZB: marginal zone B-cell, Breg: regulatory B-cell, AMZB: activated marginal zone B-
cell , FB: follicular B-cell, AB: activated B-cell, GCB: germinal center B-cell, PbB: 
plasmablast B-cell, PcB: plasma cell B-cell, MB: memory B-cell. 
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4.1.5 Clinical Implications of Molecular Diagnoses 
Our therapeutic approach was changed in 26 patients (20.6 %) from Ig replacement to 
hematopoietic stem cell transplantation (HSCT) in a selected group with atypical combined 
immunodeficiency (LRBA, DCLRE1C, RAG1, PRKCD, JAK3, PNP, CD27 and CD70 
mutations). Regular screening for cancer and avoidance of malignancy triggers were added to 
a routine management of 15 patients (11.9 %) with defects in their DNA repair system. More 
mechanistically precise treatment, such as supplementation of rapamycin in patients with 
PI3KR1, PI3KCD and LRBA deficiencies, was initiated in 22 patients. The results of WES 
aided 49 families (38.8%) in family counseling, leading to the performance of the prenatal 
diagnosis in 25 families (19.8 %). In total, a correct genetic diagnosis affected the clinical 
treatment and management of 48.4% of probands in whom a pathogenic or probably 
pathogenic variant was identified. 
4.2 NEW PHENOTYPE OF A KNOWN GENE IN DYSGAMMAGLOBULINEMIA  
Recombination-activating gene 1 (RAG1) deficiency presents with a varied spectrum of 
combined immunodeficiency, ranging from a T−B−NK+ type of disease to a T+B+NK+ 
phenotype. We sought to assess the genetic background of patients with PAD according to 
the above-mentioned method. In paper I, one of these 126 patients given an 
immunodeficiency diagnosis resembling CVID, who was born to a consanguineous family 
and thus would be expected to show an autosomal recessive inheritance, was subjected to 
clinical evaluation, immunologic assays, homozygosity gene mapping, exome sequencing, 
Sanger sequencing, and functional analysis. This 14-year-old patient had liver granuloma, 
extranodal marginal zone B-cell lymphoma, and autoimmune neutropenia. Genetic analysis 
of this patient showed a homozygous hypomorphic RAG1 mutation (p.C358Y) with a 
residual functional capacity of 48% of wild-type protein. Our finding broadens the range of 
known clinical phnotypes associated with RAG mutations and highlights that timely 
molecular diagnosis might have important therapeutic implications. 
4.3 NEW INHERITANCE PATTERN OF A KNOWN GENE IN 
DYSGAMMAGLOBULINEMIA  
In paper II, using WES analysis on a female patient born to consanguineous parent, we 
identified a novel homozygous nonsense variant in codon 56 (p.W56X) of Ras-Related C3 
Botulinum toxin substrate 2 (RAC2) protein. The same homozygous mutation was identified 
in her brother, and in a heterozygous form in their mother. Both siblings suffered from a 
CVID-like immunodeficiency in addition to hormone deficiencies, and a coagulation defect 
(factor XI deficiency). Western blot analysis showed absence of the RAC2 protein in 
designed transfection assay and functional analysis of patients’neutrophils showed decreased 
chemotaxis. We performed transmission electron microscopy and identified abnormalities of 
the neutrophil granules in milder form as described in the previously reported patients with 
missense mutations.  
Prior to our publication, only de novo dominant negative mutations affecting RAC2 (p.D57N) 
had been reported in 2 male infants with phagocytosis disorder. The first case presented with 
a complex neutrophil dysfunction disease, which was characterized by multiple and 
progressive soft-tissue infections during the first few weeks of life, neutrophilia, and a 
neutrophil chemotaxis defect.  The second case exhibited reduced numbers of Trec in the 
newborn screening, and later developed omphalitis, paratracheal abscess, and a neutrophil 
chemotaxis defect. Both infants underwent successful HSCT, therefore their humoral 
immune status were not defined. Our results illustrate that different types of mutations in a 
given gene might be associated with vastly different clinical phenotypes. 
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4.4 NEW GENE DISCOVERY IN DYSGAMMAGLOBULINEMIA 
CD27 is a member of the tumor necrosis factor receptor superfamily and is involved in a 
pathway (with its unique ligand CD70) regulating immunity versus tolerance by several 
immune mechanism including T cell expansion and survival, co-stimulation of antigen 
presentation, germinal center formation, B cell activation and antibody production. The 
clinical and immunologic features of CD27 deficiency remain obscure because only a few 
patients had been identified before this study. In paper III, we have identified novel 
mutations in CD27 (homozygous p.C96Y in two patients and homozygous p.R78W in one 
patient) during the process of the project and we sought to provide an overview of clinical, 
immunologic, and laboratory phenotypes in patients with CD27 deficiency. Review of the 
medical records and molecular, genetic, and flow cytometric analyses of the patients and 
family members were performed. Treatment outcomes of previously described patients and 
another joint cohort of 4 new patients were followed up. Epstein–Barr virus (EBV)-
associated lymphoproliferative disease, hemophagocytic lymphohistiocytosis, Hodgkin 
lymphoma, uveitis, and recurrent infections were the predominant clinical features. 
Expression of cell-surface and soluble CD27 was significantly reduced in patients and 
heterozygous family members. Immunoglobulin substitution therapy was administered in 5 of 
the newly diagnosed cases due to primary or secondary antibody deficiency. CD27 deficiency 
is potentially fatal and should be excluded in all cases of severe EBV infections to minimize 
diagnostic delay. Flow cytometric immunophenotyping offers a reliable initial test for CD27 
deficiency. Determining the precise role of CD27 in immunity against EBV might provide a 
framework for new therapeutic concepts.  
CD70 is also a co-stimulatory molecule expressed on several immune cells including T cells, 
B cells and dendritic (DC) cells, and its interaction with CD27 leads to the activation of 
CD70-positive cells via anti-apoptotic kinases. Aligned with the process of the main project 
and using a power of WES for detection of novel gene defects, in paper IV we also identified 
first human CD70 deficiency in two patients from our cohort (homozygous p.S84Pfs27X) 
and in two other patients from other ethinicity, predominantly manifesting as susceptibility to 
EBV-related diseases. Three patients presented with EBV-associated Hodgkin’s lymphoma 
and hypogammaglobulinemia mimicking a CVID phenotype; one also had severe varicella 
infection. The fourth had suspected viral encephalitis during infancy and EBV infection. 
Homozygous frameshift or in-frame deletions in CD70 in these patients abolished either 
CD70 surface expression or binding to its cognate receptor CD27. Lymphocyte numbers 
were normal, but the proportions of memory B cells and EBV-specific effector memory 
CD8+ T cells were reduced. Furthermore, although T cell proliferation was normal, in vitro-
generated EBV-specific cytotoxic T cell activity was reduced. This reflected impaired 
activation by, rather than effects during killing of EBV-transformed B cells. Thus, autosomal 
recessive CD70 deficiency is a novel cause of PID and EBV-associated diseases, reminiscent 
of CD27 deficiency. CD70-CD27 interactions therefore play a non-redundant role in T- and 
B- cells mediated immunity, especially for protection against EBV and humoral immunity. 
 
4.5 DISCUSSION AND NEW GUIDELINE IN GENETIC STUDY OF 
DYSGAMMAGLOBULINEMIA 
 
Our findings reflect that PAD is a group of clinically and genetically heterogeneous 
disorders, necessitating a wide molecular approach for a definitive diagnosis [65]. Although it 
is not yet a consensus, recent genetic diagnostic studies on undefined dysgammaglobulinemic 
patients have tried to include all known PID genes in this subgroup of PID patients using 
NGS.  
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The success rate of this approach was reported to be 23.5% in 34 UK CVID patients[17], 
30% in a US CVID cohort of 50 patients [16], and 41.6% in 36 patients in a multinational 
antibody deficiency cohort [66]. The diagnostic yield in these three NGS investigations are 
close to the results of targeted gene panel testing (15-40%, with a lower time consumption 
and cost for the latter) due to inadequate computational analysis for CNV, lack of utilization 
of the gene discovery power of NGS and lack of functional assays for confirmation of the 
pathogenicity of the observed variants  [28-31] . Although the genetic defect was identified in 
68.2% of our patients, we were not able to find the disease-causing variant in 40% of 
currently solved patients if we had used targeted sequencing for a known list of genes of PAD 
(based on the latest classification of International Union of Immunological Societies [18]). 
However, our conclusion is that a high-throughput genomic approach should be performed as 
a first screening step for patients with dysgammaglobulinemia due to the overlap of clinical 
phenotypes derived from distinct genotypes. In line with this notion, our investigation 
resulted in an expansion of the clinical spectrum of mutations in 19 genes.  
 
Of note, BTK, BLNK and µ heavy chain deficient patients with atypical presentation of the 
hypogammaglobulinemia and normal peripheral B cell counts, mimicking a CVID-like 
phenotype, indicates the potential problem using a conventional genetic approach, which is 
based on the immunoglobulin profile and lymphocyte counts. Although several efforts have 
been made during the past decade to classify dysgammaglobulinemia based on different 
clinical phenotypes and Ig  profiles, our results complement other studies suggesting an early 
and comprehensive genetic strategy (e.g. WES). Reduced penetrance or variable expressivity 
was observed in our patients with LRBA deficiency (presenting as agammaglobulinemia, 
HIgM and CVID-like phenotypes) and PI3KR1 deficiency (presenting as HIgM, CVID and 
IgAD), indicating an extension of the PID phenotype spectrum. As there is considerable 
immunologic heterogeneity in individuals with exactly the same gene defect (within 
families), this highlights the potential role of as yet unidentified modifier genes. This finding 
is also consistent with progression of different forms of dysgammaglobulinemia. 
Nonetheless, in contrast to the Ig profile, the B cell developmental pattern showed a robust 
association with the diseases associated gene (Figure 4). This general observation 
emphasizes the importance of filtering variants in collaboration with the treating clinicians 
and immunologists.  
 
On the other hand, patients with hypomorphic mutation in severe combined 
immunodeficiency associated genes (e.g. RAG1, JAK3, PRKDC and DCLRE1C) and 
incomplete and atypical presentation of syndromic disorders (e.g. associated with ZBTB24, 
DNMT3B, PGM3, DKC1, PNP and TTC7A mutations) illustrates the need for careful 
assessment of PAD patients in order to provide a reliable prognosis and to initiate appropriate 
treatment. This approach may be of considerable value in these patients, where the 
establishment of diagnosis on a molecular level would suggest a different type of therapy, 
shifting from Ig replacement to HSCT or gene therapy. Establishing a correct differential 
diagnosis list for PAD including a more broad panel of PID genes is also suggested by our 
results, as mutations in RAC2 (congenital defects of phagocyte genes with defects of 
neutrophils motility), NLRP12 and MVK (autoinflammatory disorders genes affecting the 
inflammasome), IL12RB1 and STAT2 (genes involved in intrinsic and innate immunity) and 
STAT3 (known gene involved in immune dysregulation) could manifest with an aberrant Ig 
profile. These findings and previous genetic causes reported to underlie of antibody 
deficiency in other studies, urge us to expand the expected genetic candidate of PAD. 
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In paper V, we suggested, as demonstrated in our workup chart (Figure 5), a stepwise 
clinical and molecular diagnosis in patients with different types of PAD. In a mixed group of 
antibody deficient patients, patients with gene defects that are associated with other forms of 
PID should be detected by NGS, including those with defects associated with syndromes or 
combined immunodeficiencies since they would be at risk for a high morbidity and mortality. 
However, such patients are likely to exhibit several abnormal immune parameters in addition 
to a perturbed Ig profile (Figure 6). In our suggested decision tree for the diagnostic workup, 
probable pathogenesis, and appropriate treatment choices, it is recommended to start with 
clinical/immune parameters (particularly the B cell subset pattern) whereupon it is possible to 
distinguish other or additional defects and, in some cases, a genetically defined defect. What 
is left from the cohort of antibody deficient patients will be a group of idiopathic PAD 
patients that should be investigated for other probable etiologies, including modifier genes, 
defects in enhancer, promoter and intronic regions or other structural abnormalities, low-
grade mosaicism, epigenetic markers and environmental susceptibility factors. Another 
potential factor that should be considered is inadequate coverage of the gene of interest 
(variants that have low quality or reads support less than 4 is usually filtered during analysis 
process) in some known or potential genes.  
 
The main pathways involved in our PAD patients were the post-germinal center survival 
pathway and DNA repair signaling. We calculated and plotted the network of all 189 known 
PID-causing genes related to PAD using the human genome connectome-predicted direct 
biological distance between human genes. We found that PAD related genes tend to be the 
central hub of the following signaling pathways: B-cell activation (p=2.9×10-29), antigen 
receptor-mediated signaling pathway (p=9.3×10-24), activating cell surface receptor signaling 
pathway (p=1.1×10-21), and lymphocyte differentiation (p=2.0×10-21). 
 
Additional capabilities of NGS on In silco analysis of CNV and detection of new candidate 
genes provide further support for this approach as the first step in the genetic diagnosis of 
PAD. Lack of identification of disease-causing CNVs, particularly in compound 
heterozygous forms in cohorts with a large proportion of non-consanguineous patients, could 
be a potential explanation for differences in diagnostic yield between our survey and other 
studies [16, 17]. Although we found that 4.6% of the solved cases harbored large 
homozygous deletions (mainly within the LRBA and DOCK8 genes with a high level content 
of transposable elements [67]), it supports the notion of a potential presence of a selected 
group of antibody deficient patients with biallelic defects due to an allele with large 
heterozygous deletion from one parent together with an allele defective due to a mutation 
from another parent. Similar findings have been shown in a recent study investigating 
different categories of PID, revealing an approximately 10% mutational burden of CNV in 
diseases pathogenesis [66]. Although different methods could ultimately be integrated into 
the diagnostic process, a computational algorithm for NGS analysis might be an appropriate 
and cost effective method for CNV detection as previously described [39, 68].  
 
Despite advances in CNV analysis and novel gene hunting algorithms in NGS, we also 
evaluated other potential factors that may affect the diagnostic yield rates in our study as 
compared to other reports. The effect of severe clinical phenotype, use of homozygosity 
mapping, and even parental consanguinity could not explain this level of difference 
(comparing 40 unsolved to 86 solved patients). However, familial segregation analysis 
including a healthy sibling or another first-degree relative using NGS in multiple case 
families could increase the discovery rate, being more efficient than trios, a fact which seems 
to be consistent among different studies with different settings [16, 17, 66].  
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Figure 5- A Clinical, immunological and genetic approach for a molecular diagnosis of 
primary antibody deficiency 
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Figure 6- Candidate gene defects and pathological mechanisms in patients with primary 
antibody deficiency based on clinical and immunological phenotyping and their appropriate 
treatment modalities. AH50: 50% alternative haemolytic complement activity, KREC: kappa-
deleting recombination excision circle,  CARD: Caspase recruitment domain, EBV: Epstein–
Barr virus, CH50: 50% haemolytic complement activity, FFP: fresh frozen plasma, G-CSF: 
granulocyte-colony stimulating factor, HSCT: Hematopoietic stem cell transplantation, 
iNKT: invariant NK-T cells, IgR: immunoglobulin replacement therapy, IFN-g: interferon 
gamma, LPD: lymphoproliferative disorder, TLR: Toll-like receptors, TNF: tumor necrosis 
factor; TREC: T-cell receptor excision circle. References reviewed for compiling the gene list 
underlying dysgammaglobulinemia were [16-19, 7, 10]. 
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Whole genome sequencing (WGS) enables an advanced CNV detection (in the case of PCR 
free library preparation), and targeting all arbitrary exome, deep intronic, regulatory domains 
and structural intragenic regions (due to the absence of capture step and reference biases). For 
the time being, however, WES seems to be the most cost effective approach for PAD patients 
with unknown etiology [32]. 
 
Our follow-up on patients with a molecular diagnosis using NGS provided valuable guidance 
for the treating physicians towards appropriate clinical management, prenatal diagnosis, and 
targeted therapy (where recent studies have been provided evidence for utilization of 
rapamycin, abatacept and tocilizumab as new modalities in the treatment of PAD [69-71]). 
Prenatal diagnosis in childhood-onset patients has an important significance apart from 
decreasing the burden of diseases, since the parents and also the first relatives of patients are 
still in childbearing ages and may thus need genetic counseling for their next pregnancy. 
Furthermore, a selected group of patients with symptoms suggesting a combined 
immunodeficiency could potentially benefit from HSCT, including those with mutations in 
RAG1, CD27 and CD70.  
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5 CONCLUSION AND FUTURE PRESPECTIVES 
Although our gene hunting was conducted on a national patient cohort from the Middle East 
region, the mutated genes from this region have also been documented in western non-
consanguineous populations where they have been reported in compound heterozygous 
forms. We suggest that NGS could replace the conventional multistep genetic approach 
because it can expanded to cover all known PID associated genes and potentially detect CNV 
and new genes associated with primary immunodeficiency. More efforts should be spent on 
improving the NGS processing timeframe and gene-capture coverage to integrate it in a rapid 
molecular diagnostic pipeline, including the confirmation of a positive newborn screening 
test. Despite a substantial decrease in the cost for NGS in recent years, it still somewhat 
hampers its large scale implementation although this is expected to change within the 
foreseeable future. 
Dysgammaglobulinemia, particularly CVID, is likely to be a collection of several genetically 
distinct disorders. Although all the patients in our cohort could not be shown to suffer from a 
monogenic disorder, these patients should be further investigated for additional, non-genetic 
susceptibility factors. 
In parallel, regarding patients without identified gene even after WES, we will continue to 
investigate the “genome” of the patients with WGS. In a same time we will try to improve 
our computational pipeline analysis on NGS.  However, my future projects will involve 
mainly on establishing single cell methods for “transcriptome” and “proteome” analysis of 
patients whom we have discovered novel gene defect to empower our functional assays and 
to assess the subsequent molecular events downstream of defect in specific cells. 
For PAD patients with gene defects in epigenetic controlling pathways whom evaluated 
currently by DNA methylome profile (data not shown in this summary), we will continue to 
expand the level of “epigenome” investigation to find alteration in histone modification and 
miRNA profile. The auto-antibodies against major cytokines for development of B cells and 
high-throughput major histocompatibility typing are other potential factors that will be 
investigated in the unsolved patients. 
Genes affecting the mucosal immunity as well as Ig production will be subjected for 
performing “microbiome”, particularly in patients with enteropathies.  
Patients with defect in genes involved in DNA repair system will be subjected for 
“immunome” profile using high throughput techniques for investigation of total B- and T-cell 
receptor repertoire and rearrangement composition, switch junctions, double strand breakage 
point and somatic hyper mutation profile. 
Moreover we will continue preforming WES on additional probands with primary antibody 
deficiency especially with a diagnosis of IgAD, IgG subclass deficiency, specific antibody 
deficiency patient and transient hypogammaglobulinemia of infancy. 
The output of this doctoral thesis will add more information about the genetic association of 
PAD, enabling earlier diagnosis and management of patients and their relatives. As above-
mentioned, molecular diagnosis plays a pivotal in PAD diagnosis (e.g. identification of new 
genetic defects, distinguishing genetic form from an acquiring disorder, confirming the 
clinical diagnosis, positive newborn screening test and pattern of inheritance, pre-
symptomatic diagnosis, cascade screening of at-risk relatives and population based screening, 
identifying novel or atypical phenotype of a known gene defect), assisting treatment decisions 
(e.g. hematopoietic stem cell transplantation, metabolite change or supplementation,  new 
targeted medication and gene therapy),  prognosis estimation (e.g. long-term prospective of 
treatment) and possibility of family counseling (e.g. prenatal diagnosis and  pre-implantation 
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genetic diagnosis). The therapeutic approach was changed from Ig replacement to HSCT in a 
selected group of patients with atypical combined immunodeficiency.  Regular screening for 
cancer and avoidance of malignancy triggers were added to a routine management of patients 
with deficiencies in DNA repair system. More precise mechanistically and targeted treatment 
was initiated and the results of this study aided several families for family consulting, 
particularly for prenatal diagnosis. Generally multomics approach is the future diagnostic and 
therapeutic horizon in patients with PAD, PID and other type of rare inherited disorders. 
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